This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leger, J. Articles by Czernichow, P. Search for Related Content PubMed PubMed Citation Articles by Leger, J. Articles by Czernichow, P.

Human Growth Hormone Treatment of Short-Stature Children Born Small for Gestational Age: Effect on Muscle and Adipose Tissue Mass during a 3-Year Treatment Period and after 1 Year’s Withdrawal

Pediatric Endocrinology and Diabetes Unit (J.L., A.F.-P., P.C.), Radiology Department (C.G., M.H.), INSERM U457, Hôpital Robert Debré, 75019 Paris, France.

Address all correspondence and requests for reprints to: Juliane Leger, M.D., Pediatric Endocrinology and Diabetes Unit, Hôpital Robert Debré, 48, Bd Sérurier, 75019 Paris, France.

In addition to its growth promoting effect, GH has profound metabolic effects that have not always been evaluated in longitudinal studies. We have recently shown that the effect of GH on body composition can be evaluated by magnetic resonance imaging measurement of adipose and muscle tissue cross-sectional (cs) areas in the thigh.

The aim of this study was to evaluate the long-term effects of human GH (hGH) (0.2 IU/kg·day) on muscle and adipose tissue mass during a 3-yr treatment period and after 1 year’s withdrawal in short SGA (small for gestational age) children. Measurement of muscle and fat tissue mass by magnetic resonance imaging of the thighs was used to study the metabolic effect of hGH in 14 prepubertal short children born SGA. Results were compared with those of a control group of 7 normal children followed longitudinally.

An increase of muscle tissue cs area was observed during the 3 yr of hGH treatment, an increase which was significantly different during the first 2 yr of treatment from that seen in controls (+31.2 ± 2.6% and +18.1 ± 1.8% during the 1st and 2nd year, respectively, vs. +9.1 ± 2.6% change during 1 yr in controls). After a significant decrease in adipose tissue cs area during the first year of therapy (^-16.4 ± 3.4% vs. baseline values), an increase in adipose tissue cs area occurred during the second and third years. At the end of the third year, the muscle tissue cs area change was significantly greater in SGA-treated children, as compared with controls (+71.6 ± 4.6% vs. 22.1 ± 4.6%; P < 0.001), whereas the adipose tissue cs area change was similar in the two groups (+12.6 ± 9.5% vs. +19.9 ± 4.2%).

After hGH withdrawal, the effects were opposite after 3 months, as compared with those observed after the first 3 months of hGH administration, whereas no additional significant change was seen after 1 yr off treatment, indicating the maintenance of muscle and adipose tissue mass.

In conclusion, hGH administered to SGA children is effective in improving growth velocity and has long-term effects on muscle and adipose tissue mass. These effects may lead to speculation about the sensitivity of these tissues to GH. The physiological consequences of such effects must be evaluated.

This article has been cited by other articles:

				P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]

				R. H. Willemsen, M. van Dijk, Y. B. de Rijke, A. W. van Toorenenbergen, P. G. Mulder, and A. C. Hokken-Koelega Effect of Growth Hormone Therapy on Serum Adiponectin and Resistin Levels in Short, Small-for-Gestational-Age Children and Associations with Cardiovascular Risk Parameters J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 117 - 123. [Abstract] [Full Text] [PDF]

				M. van Dijk, E. M. N. Bannink, Y. K. van Pareren, P. G. H. Mulder, and A. C. S. Hokken-Koelega Risk Factors for Diabetes Mellitus Type 2 and Metabolic Syndrome Are Comparable for Previously Growth Hormone-Treated Young Adults Born Small for Gestational Age (SGA) and Untreated Short SGA Controls J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 160 - 165. [Abstract] [Full Text] [PDF]

				L B Johnston and M O Savage Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch. Dis. Child., August 1, 2004; 89(8): 740 - 744. [Abstract] [Full Text] [PDF]

				P. A. Lee, J. W. Kendig, and J. R. Kerrigan Persistent Short Stature, Other Potential Outcomes, and the Effect of Growth Hormone Treatment in Children Who Are Born Small for Gestational Age Pediatrics, July 1, 2003; 112(1): 150 - 162. [Full Text] [PDF]

				M J Rennie Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes? Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105. [Abstract] [Full Text] [PDF]

				T. Sas, P. Mulder, and A. Hokken-Koelega Body Composition, Blood Pressure, and Lipid Metabolism before and during Long-Term Growth Hormone (GH) Treatment in Children with Short Stature Born Small for Gestational Age Either with or without GH Deficiency J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3786 - 3792. [Abstract] [Full Text]